A Study of HS-20094 Versus Dulaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabete
Phase 3 trial tests HS-20094, a once-weekly GLP-1 receptor agonist, versus dulaglutide in 546 adults with type 2 diabetes inadequately controlled on metformin alone or with SGLT2 inhibitors. Open-label comparison running 52 weeks with HbA1c reduction as primary endpoint, completion expected March 2027. Jiangsu Hansoh enters the competitive once-weekly GLP-1 space dominated by Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, targeting the large metformin-failure population. Direct head-to-head with dulaglutide positions this Chinese biosimilar for potential market share in Asia-Pacific regions.